Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics

被引：4
|
作者：
Sarah, Allegra [1 ,2 ]
Dondi, Emma [1 ]
De Francia, Silvia [1 ]
机构：
[1] Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, Orbassano, TO, Italy
[2] Univ Turin, San Luigi Gonzaga Hosp, Dept Clin & Biol Sci, Clin Pharmacol Serv Franco Ghezzo, Reg Gonzole 10, I-10043 Turin, TO, Italy
来源：
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2023年 / 19卷 / 11期
关键词：
Chemotherapy; Cancer; Precision Medicine; Personalized Treatment; IMATINIB;
D O I：
10.1080/17425255.2023.2277758
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：733 / 739
页数：7
相关论文
共 50 条
  • [31] Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics
    Hoshino-Yoshino, Azusa
    Kato, Motohiro
    Nakano, Kohnosuke
    Ishigai, Masaki
    Kudo, Toshiyuki
    Ito, Kiyomi
    DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (06) : 612 - 620
  • [32] Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors
    Choi, Yongmun
    Syeda, Farisa
    Walker, John R.
    Finerty, Patrick J., Jr.
    Cuerrier, Dominic
    Wojciechowski, Amy
    Liu, Qingsong
    Dhe-Paganon, Sirano
    Gray, Nathanael S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) : 4467 - 4470
  • [33] Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
    Joerg Herrmann
    Current Oncology Reports, 2016, 18
  • [34] Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
    Herrmann, Joerg
    CURRENT ONCOLOGY REPORTS, 2016, 18 (06)
  • [35] Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
    Ichim, Christine Victoria
    STEM CELLS TRANSLATIONAL MEDICINE, 2014, 3 (04) : 405 - 415
  • [36] Small molecule tyrosine kinase inhibitors:: Potential role in pediatric malignant solid tumors
    Roesler, Jochen
    Geoerger, Birgit
    Taylor, Melissa
    Vassal, Gilles
    CURRENT CANCER DRUG TARGETS, 2008, 8 (01) : 76 - 85
  • [37] Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors
    Vaziri, Susan A. J.
    Kim, Jenny
    Ganapathi, Mahrukh K.
    Ganapathi, Ram
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 102 - 108
  • [38] The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology
    Touma, Josephine A.
    McLachlan, Andrew J.
    Gross, Annette S.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1558 - +
  • [39] Tyrosine Kinase Inhibitors and Male Reproductive Health
    Ramstein, Joris J.
    Tsai, Katy K.
    Smith, James F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (05) : 754 - 756
  • [40] Thyroid dysfunctions induced by tyrosine kinase inhibitors
    Fallahi, Poupak
    Ferrari, Silvia M.
    Vita, Roberto
    Di Domenicantonio, Andrea
    Corrado, Alda
    Benvenga, Salvatore
    Antonelli, Alessandro
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (06) : 723 - 733
12345